Priced at $125,000 per injection and $750,000 for the first year of treatment, Biogen Inc.’s Spinraza (nusinersen) is the the first US FDA-approved treatment for rare spinal muscular atrophy (SMA), and now the company is looking to bring the high-priced drug to China.
Riding the country’s surging wave of new therapies and accelerated approvals for critical and rare disease treatments, the US biotech has unveiled ambitious plans including setting up local operations, hiring...